Citi Downgrades Moonlake Immunotherapeutics (MLTX) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Unity Software stock soars 22% on strong Q3 beat, robust guidance
Tweet
Share
E-mailGet Alerts MLTX Hot Sheet
Price: $11.56 --0%
Rating Summary:
12 Buy, 4 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
12 Buy, 4 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
Citi analyst Samantha Semenkow downgraded Moonlake Immunotherapeutics (NASDAQ: MLTX) from Neutral to Sell with a price target of $5.00.
For an analyst ratings summary and ratings history on Moonlake Immunotherapeutics click here. For more ratings news on Moonlake Immunotherapeutics click here.
Shares of Moonlake Immunotherapeutics closed at $9.82 yesterday.
You May Also Be Interested In
- Freedom Broker Downgrades Black Hills Corp (BKH) to Hold on Valuation
- Evercore ISI Downgrades MNTN Inc (MNTN) to In Line
- MoonLake Immunotherapeutics (MLTX) Misses Q3 EPS by 15c
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
